Incidence of Transmitted Antiretroviral Drug Resistance in Treatment-Naive HIV-1-Infected Persons in a Large South Central United States Clinic

Annals of Pharmacotherapy

Volumn 48, Issue 4, 2014, Pages 470-475

  Kleyn, Thomas J ^a   Liedtke, Michelle D ^b   Harrison, Donald L ^b   Lockhart, Staci M ^b   Salvaggio, Michelle R ^b   Ripley, Toni L ^b   Rathbun, R Chris ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

antiretroviral; drug resistance; HIV 1; Oklahoma; transmission

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; ARTICLE; DRUG RESISTANCE; FEMALE; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POINT MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RURAL POPULATION; TRANSMITTED DRUG RESISTANCE; UNITED STATES; ADOLESCENT; AGED; ANTIVIRAL RESISTANCE; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; GENOTYPE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MUTATION; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; OKLAHOMA; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 84898684043     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013519246     Document Type: Article

References (19)

1. Palella FJ,Delaney KM,Moorman AC, et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med. 1998;338:853-860.
2. Hirsch MS,Günthard HF,Schapiro JM, et al.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Clin Infect Dis. 2008;47:266-285.
3. Wheeler WH,Ziebell RA,Zabina H, et al.Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.AIDS. 2010;24:1203-1212.
4. Wittkop L,Günthard HF,de Wolf F, et al.Effect of transmitted drug resistance on virological and immunological response to initiation combination antiretroviral therapy for HIV (EuroCord-CHAIN joint project): a European multicohort study.Lancet Infect Dis. 2011;11:363-371.
5. Hurt CB,McCoy SI,Kuruc J, et al.Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina, 1998 to 2007.Antivir Ther. 2009;14:673-678.
6. Shet A,Berry L,Mohri H, et al.Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1.J Acquir Immune Defic Syndr. 2006;41:439-446.
7. Johnson VA,Calvez V,Günthard HF, et al.2011 update of the drug resistance mutations in HIV-1.Top Antivir Med. 2011;19:156-164.
8. Bennett DE,Camacho RJ,Otelea D, et al.Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.PLoS One. 2009;4:e4724.
9. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011, Vol. 23. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published February2013. Accessed April 8, 2013.
10. Jain V,Liegler T,Vittinghoff E, et al.Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.PLoS One. 2010;5:e15510.
11. Yerly S,Junier T,Gayet-Ageron A, et al.The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection.AIDS. 2009;23:1415-1423.
12. Grant RM,Hecht FM,Warmerdam M, et al.Time trends in primary HIV-1 drug resistance among recently infected persons.JAMA. 2002;288:181-188.
13. Simon V,Vanderhoeven J,Hurley A, et al.Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.AIDS. 2002;16:1511-1519.
14. Anta L,Llibre JM,Peveda E, et al.Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.AIDS. 2013;27:81-85.
15. Haddad M,Napolitano LA,Paquet AC, et al.Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility.Antivir Ther. 2011;16:A18.
16. Sluis-Cremer N,Huber K,Brumme C,Wallis C,Mellors J,Harrigan R.The E138A mutation in HIV-1 reverse transcriptase is more common in subtype C than B and decreases susceptibility to NNRTI. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA;.
17. Hurt CB,Sebastian J,Hicks CB,Eron JJ.Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.Clin Infect Dis. 2013;:.
18. Lennox JL,DeJesus E,Lazzarin A, et al.Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial.Lancet. 2009;374:796-806.
19. Raffi F,Rachlis A,Stellbrink HJ, et al.Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.Lancet. 2013;381:735-743.